Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide plus azacitidine maintenance in AML remission
ACTRN12611000110987Phase 2Completed
- Sponsor
- Andrew Wei
- Start
- Jan 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of lenalidomide and azacitidine in acute myeloid leukemia (AML) (7 cohorts), sponsored by Andrew Wei. Primary endpoints: Maximum tolerated dose of lenalidomide in combination with 5-day azacitidine and Dose-limiting toxicities. Started Jan 2010; status: completed.
02
Drugs
lenalidomideazacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ACTRN12611000110987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611000110987.